News | May 23, 2024
Merck to acquire life science company Mirus Bio for US$ 600 million
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Sales reflect continued strong growth in oncology and vaccines
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Subscribe To Our Newsletter & Stay Updated
